Laurus Labs receives EIR for API units 1 & 3 at Parawada, Visakhapatnam

Laurus Labs has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1&3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.

And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).

Powered by Capital Market - Live News